To better understand the mechanism whereby MEK and BET inhibitors cooperate to inhibit the growth of NRAS‐mutant melanoma, we performed RNA‐sequencing and proteomic analysis of cells treated with single‐agent JQ‐1, PD901, or the combination of both drugs. Here, NRAS is linked to melanoma.